Abstract
Tyrosine kinase receptors are expressed on the surface of tumor and/or endothelial cells and represent attractive targets for new anti-cancer treatment strategies. The so-called “small molecule” tyrosine kinase inhibitors have been designed to interact with the intracellular ATP binding site of these receptors, subsequently causing arrest of tumor cell proliferation, as well as induction of apoptosis and tumor migration. Furthermore, these molecules can impact on tumor angiogenesis. Tyrosine kinase inhibitors have been evaluated in several clinical trials for various adult malignant tumor entities and are currently being studied in pediatric solid malignancies. In this review, we will address the data available supporting the potential use of tyrosine kinase inhibitors in solid malignancies of childhood.
Keywords: Tyrosine kinase, tyrosine kinase inhibitors, imatinib, gefitinib, erlotinib, embryonic tumors, sarcomas, pediatric oncology
Current Cancer Drug Targets
Title: Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Volume: 8 Issue: 1
Author(s): Jochen Rossler, Birgit Geoerger, Melissa Taylor and Gilles Vassal
Affiliation:
Keywords: Tyrosine kinase, tyrosine kinase inhibitors, imatinib, gefitinib, erlotinib, embryonic tumors, sarcomas, pediatric oncology
Abstract: Tyrosine kinase receptors are expressed on the surface of tumor and/or endothelial cells and represent attractive targets for new anti-cancer treatment strategies. The so-called “small molecule” tyrosine kinase inhibitors have been designed to interact with the intracellular ATP binding site of these receptors, subsequently causing arrest of tumor cell proliferation, as well as induction of apoptosis and tumor migration. Furthermore, these molecules can impact on tumor angiogenesis. Tyrosine kinase inhibitors have been evaluated in several clinical trials for various adult malignant tumor entities and are currently being studied in pediatric solid malignancies. In this review, we will address the data available supporting the potential use of tyrosine kinase inhibitors in solid malignancies of childhood.
Export Options
About this article
Cite this article as:
Rossler Jochen, Geoerger Birgit, Taylor Melissa and Vassal Gilles, Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors, Current Cancer Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/156800908783497113
DOI https://dx.doi.org/10.2174/156800908783497113 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies of Development of Antiviral Agents Directed Against Influenza Virus Replication
Current Pharmaceutical Design Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Epigenetic and Genetic Mechanisms of Abnormal 11p15 Genomic Imprinting in Silver-Russell and Beckwith-Wiedemann Syndromes
Current Medicinal Chemistry Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Gastroenterological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Dendritic Cells in Innate Immune Responses Against HIV
Current Molecular Medicine Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma
Current Drug Targets Chest Pain in Children
Current Pediatric Reviews Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Contemporary Pediatric Palliative Care: Myths and Barriers to Integration into Clinical Care
Current Pediatric Reviews Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets
Current Pharmaceutical Design Xenograft models of primary acute myeloid leukemia for the development of imaging strategies and evaluation of novel targeted therapies.
Current Pharmaceutical Biotechnology RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Haemozoin Formation as a Target for the Rational Design of New Antimalarials
Drug Design Reviews - Online (Discontinued) Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents